2024
P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki E, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study. EJNMMI Research 2024, 14: 123. PMID: 39636350, PMCID: PMC11621262, DOI: 10.1186/s13550-024-01186-3.Peer-Reviewed Original ResearchPerilesional rimTracer bindingDisability progressionMS patientsMS brainsLesion rimWhite matterProgressive MS patientsPro-inflammatory microgliaRelapsed patientsSmoldering inflammationT1 lesionsMales compared to femalesNew-onsetProgressive patientsTracer uptakeParent tracerP2XDisease durationProgressive MSHealthy controlsPatientsPET studiesPerilesional areaFree fraction
2022
TSPO-PET-measurable Microglial Activation Associates with Serum 3-hydroxykynurenine Levels in Multiple Sclerosis Patients (P14-4.007)
Saraste M, Matilainen M, Sucksdorff M, Rajda C, Galla Z, Vécsei L, Airas L. TSPO-PET-measurable Microglial Activation Associates with Serum 3-hydroxykynurenine Levels in Multiple Sclerosis Patients (P14-4.007). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2556.Peer-Reviewed Original ResearchPhase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003)
Wiendl H, Airas L, Chitnis T, Williams M, Nakahara J, Bermel R, Mann A, Ziehn M, Bhatt A, Hunter B, Zhang Y, Karan R, Willi R, Kieseier B, Montalban X. Phase 3 REMODEL I/II Trials: Effectiveness, Safety, and Tolerability of Remibrutinib in Patients with Relapsing Multiple Sclerosis (P7-4.003). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.2562.Peer-Reviewed Original Research
2020
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807)
Wolinsky J, Brochet B, Hartung H, Naismith R, Airas L, Coutant K, Koendgen H, Manfrini M, Overell J, Sauter A, Prajapati K, Kappos L. Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive MS Treated with Ocrelizumab: 6.5-study Year Follow-up Data (1807). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1807.Peer-Reviewed Original ResearchEffect of Dopaminergic Medication on Adenosine 2A Receptor Availability in Patients with Parkinson’s Disease (30)
Waggan I, Tuisku J, Matilainen M, Helin S, Parkkola R, Rissanen E, Rinne J, Airas L. Effect of Dopaminergic Medication on Adenosine 2A Receptor Availability in Patients with Parkinson’s Disease (30). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.30.Peer-Reviewed Original Research
2019
Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091)
Giovannoni G, Airas L, Bove R, Boyko A, Cutter G, Hobart J, Kuhle J, Oh J, Tur C, Garas M, Model F, Manfrini M, Wolinsky J. Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design (P3.2-091). Neurology 2019, 92 DOI: 10.1212/wnl.92.15_supplement.p3.2-091.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply